Seattle Genetics Inc (SGEN.OQ) Quote| Reuters.com
Edition:
United States

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

37.59USD
24 Jun 2016
Change (% chg)

-- (--)
Prev Close
$37.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
385,279
52-wk High
$52.19
52-wk Low
$26.02

SGEN.OQ

Chart for SGEN.OQ

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $5,268.88
Shares Outstanding(Mil.): 140.17
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -0.91 -- --
ROI: -22.19 -5.72 14.23
ROE: -26.70 -4.83 15.46

BRIEF-Astellas, Seattle Genetics present clinical data in metastatic urothelial cancer

June 6 Astellas Pharma Inc and Seattle Genetics Inc :

Jun 06 2016

BRIEF-Seattle Genetics Q1 loss per share $0.15

* Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S

Apr 28 2016

BRIEF-Seattle Genetics CEO's 2015 total compensation was $6.87 mln vs $6.86 mln in 2014 - SEC Filing

* CEO Clay B. Siegall 2015 total compensation of $6.87 million versus $6.86 million in 2014 - SEC Filing Source text for Eikon: (http://1.usa.gov/1XhKT0X) Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 06 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.